Picard Medical cuts net loss 79% to $2.219 million in third quarter
Key Facts
Picard Medical cut its net loss in the third quarter of 2026 by 79% year over year to $2.219 million, from $10.426 million in the same period of 2025, according to its quarterly filing with the U.S. Securities and Exchange Commission. The decline coincided with gross profit of $95,000, compared with a gross loss of $130,000 a year earlier. But the improvement in net loss and gross profit was not accompanied by product sales during the quarter. The company attributed the absence of those sales to there being no eligible patients scheduled at its hospital customers. PMI shares closed at $7.24 on November 16, according to EL7 data.
The company said its customer hospitals had no eligible patients scheduled during the period, preventing product sales from being recorded. It added that the absence of sales did not result from order cancellations, lost customers or a known negative trend in demand. This explanation places the quarter in the context of the timing of eligible cases at hospitals, while product revenue remained absent from the quarterly results. By contrast, the comparison showed an improvement in gross profit, with the company moving from a loss of $130,000 in the third quarter of 2025 to a profit of $95,000 in the third quarter of 2026. For the first nine months of 2026, gross profit was $986,000, compared with a gross loss of $615,000 in the same period a year earlier.
The improvement in gross profit coincided with a $0.6 million, or 66%, reduction in research and development expenses in the third quarter compared with the same period of 2025. Management attributed the decline mainly to reduced activity and the rescheduling of milestones for new product research. This means the expense reduction was partly accompanied by slower research work and rescheduled milestones, rather than growth in product sales during the quarter. These details matter when assessing the decline in net loss, as they identify one factor that accompanied the improvement in the bottom-line result. The absence of product sales remains a parallel fact alongside the lower expenses, according to the company’s report.
On liquidity, cash and cash equivalents stood at $67,000 on September 30, 2026, compared with $7.451 million on December 31, 2025. In the nine months ended September 30, 2026, operating activities used net cash of $7.148 million, compared with $11.296 million in the same period of 2025. Although net cash used in operations declined between the two periods, the cash balance at the end of September was far below its level at the end of the previous year. The company said it will need to raise additional financing through debt or equity issuance or commercial arrangements to continue its business plan. It warned that financing may not be available or obtainable on favorable terms.
Picard Medical expected product sales in the three months ended December 31, 2026, to exceed the $0.9 million recorded in the comparable quarter of 2025. The company based this on its preliminary results and confirmed orders as of November 12, 2026. It said the forecast relied mainly on orders for total artificial hearts. The outlook follows a quarter in which no product sales were recorded, while the company said their absence was not due to order cancellations, lost customers or a known trend of declining demand. Exceeding the previous fourth-quarter sales level remains the indicator the company set for the coming period, alongside its stated need for additional financing to pursue its plan.